Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma

Daniela Damasceno, Julia Almeida, the TiMaScan Study Group, Cristina Teodosio, Luzalba Sanoja‐flores, Andrea Mayado, Alba Pérez‐pons, Noemi Puig, Paula Arana, Bruno Paiva, Fernando Solano, Alfonso Romero, Sergio Matarraz, Wouter B.L. van den Bossche, Juan Flores‐montero, Brian Durie, Jacques J.M. van Dongen, Alberto Orfao*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
68 Downloads (Pure)

Abstract

Background. Monocyte/macrophages have been shown to be altered in monoclonal gam-mopathy of undetermined significance (MGUS), smoldering (SMM) and active multiple myeloma (MM), with an impact on the disruption of the homeostasis of the normal bone marrow (BM) mi-croenvironment. Methods: We investigated the distribution of different subsets of monocytes (Mo) in blood and BM of newly‐diagnosed untreated MGUS (n = 23), SMM (n = 14) and MM (n = 99) patients vs. healthy donors (HD; n = 107), in parallel to a large panel of cytokines and bone‐associ-ated serum biomarkers. Results: Our results showed normal production of monocyte precursors and classical Mo (cMo) in MGUS, while decreased in SMM and MM (p ≤ 0.02), in association with lower blood counts of recently‐produced CD62L+ cMo in SMM (p = 0.004) and of all subsets of (CD62L+, CD62L and FcεRI+) cMo in MM (p ≤ 0.02). In contrast, intermediate and end‐stage non-classical Mo were increased in BM of MGUS (p ≤ 0.03), SMM (p ≤ 0.03) and MM (p ≤ 0.002), while normal (MGUS and SMM) or decreased (MM; p = 0.01) in blood. In parallel, increased serum levels of interleukin (IL)1β were observed in MGUS (p = 0.007) and SMM (p = 0.01), higher concentrations of serum IL8 were found in SMM (p = 0.01) and MM (p = 0.002), and higher serum IL6 (p = 0.002), RANKL (p = 0.01) and bone alkaline phosphatase (BALP) levels (p = 0.01) with decreased counts of FcεRI+ cMo, were restricted to MM presenting with osteolytic lesions. This translated into three dis-tinct immune/bone profiles: (1) normal (typical of HD and most MGUS cases); (2) senescent‐like (increased IL1β and/or IL8, found in a minority of MGUS, most SMM and few MM cases with no bone lesions); and (3) pro‐inflammatory‐high serum IL6, RANKL and BALP with significantly (p = 0.01) decreased blood counts of immunomodulatory FcεRI+ cMo‐, typical of MM presenting with bone lesions. Conclusions: These results provide new insight into the pathogenesis of plasma cell neoplasms and the potential role of FcεRI+ cMo in normal bone homeostasis.

Original languageEnglish
Article number1454
Pages (from-to)1-18
Number of pages18
JournalCancers
Volume13
Issue number6
DOIs
Publication statusPublished - 22 Mar 2021

Bibliographical note

Funding Information:
This research was funded by the Biomedical Research Networking Center Consortium? CIBER?CIBERONC (CB16/12/00400, CB16/12/00369 and CB16/12/00233?FEDER), PI13/01412? FEDER, from the Instituto de Salud Carlos III (ISCIII), Ministerio de Econom?a y Competitividad, Madrid, Spain; the European Research Council (ERC) under the European Union?s Horizon 2020 Research and Innovation Programme (grant agreement ERC?2015?AdG 695655 (TiMaScan); and the Black Swan Research Initiative of the International Myeloma Foundation (Los Angeles, CA, USA), (grant IMF13/IMF16).

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

Fingerprint

Dive into the research topics of 'Monocyte subsets and serum inflammatory and bone-associated markers in monoclonal gammopathy of undetermined significance and multiple myeloma'. Together they form a unique fingerprint.

Cite this